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ABSTRACT 
The antithrombotic management of patients on oral anticoagulation (OAC), with either 
warfarin or non vitamin K-antagonist oral anticoagulants (NOACs), undergoing percutaneous 
coronary intervention with stent (PCI-S) has been recently addressed in a joint European 
consensus document. In accordance, triple therapy (TT) of OAC, aspirin and clopidogrel should 
generally be given as the initial therapy. More uncertainty exists over whether warfarin or a NOAC 
should be added in patients already on dual antiplatelet therapy of aspirin and clopidogrel (DAPT) 
after recent PCI-S. Upon review of available data, it appears that the risk of major bleeding of TT as 
compared to DAPT is similar with either warfarin or a NOAC. In particular, TT consistently appears 
associated to an approximately 2.5 fold increase in the risk of major bleeding. Because of the 
higher convenience, NOACs might be considered the preferred OAC to be added to DAPT. Given 
the reported different safety profile of the various NOACs on the incidence of major, and 
gastrointestinal, bleeding, the NOACs, and the dose, showing the greatest safety in this regard 
should be selected. In accordance, dabigatran 110 mg and apixaban 2.5 mg twice daily appear as 
the most valuable options in patients who are not and who are respectively, at increased risk of 
bleeding. As an alternative, apixaban 5 mg twice daily might be considered in patients at risk of 
bleeding not increased, whereas rivaroxaban 15 mg once daily may be considered in the presence 
of increased risk of bleeding (essentially when related to moderate renal impairment).   
 
 
KEY WORDS: warfarin, non vitamin K-antagonist oral anticoagulants, triple therapy, stent, 
percutaneous coronary intervention 
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1. INTRODUCTION 
The management of the antithrombotic therapy following percutaneous coronary 
intervention with stent (PCI-S) in patients with atrial fibrillation (AF) on oral anticoagulation (OAC) 
with warfarin has been recently addressed in a joint consensus document issued by the European 
Society of Cardiology (ESC) Working Group on Thrombosis, European Association of Percutaneous 
Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and the 
European Association of Acute Cardiac Care (ACCA), and endorsed by the Heart Rhythm Society 
(HRS) and the Asia-Pacific Heart Rhythm Society (APHRS) (1). In accordance, triple therapy (TT) of 
warfarin, aspirin and clopidogrel should generally be given as the initial therapy, the duration of TT 
should be as short as possible (based on the clinical setting in which PCI-S has been performed, the 
type of stent implanted and the patient’s risk of bleeding), and the intensity of OAC (i.e., the target 
International Normalized Ratio [INR]) should be reduced as long as TT is ongoing (1). Also, newer 
P2Y12-receptor inhibitors, including ticagrelor and prasugrel, should be avoided as part of TT (1), 
and gastric protection with proton-pump inhibitors should be extensively used throughout TT (1, 
2). 
Both by analogy with warfarin and because in the clinical trials where they were compared 
with warfarin for the prevention of stroke/systemic embolism in AF, currently available non 
vitamin-K antagonists oral anticoagulants (NOACs) (including the direct thrombin inhibitor 
dabigatran and the direct factor Xa inhibitors rivaroxaban and apixaban) (3), proved at least as 
effective and safe as (and more convenient than) warfarin (4-6) (Table 1), recommendations 
similar to those given for patients on warfarin undergoing PCI-S are also given for patients on 
NOACs (1, 7). In summary, TT of NOAC, aspirin and clopidogrel should be generally prescribed as 
the initial therapy, the duration of the given TT should be as short as possible (again based on the 
clinical setting in which PCI-S has been performed, the type of stent implanted and the patient’s 
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risk of bleeding), and the intensity of OAC (i.e., the dose of NOAC) should be reduced as long as TT 
is ongoing (1, 7). Avoidance of the newer P2Y12-receptor inhibitors ticagrelor and prasugrel as part 
of TT (1, 7), and extensive use of proton-pump inhibitors during TT are again recommended (1, 2, 
7). 
In practical terms, the above implies that an AF patient on OAC, with either warfarin or 
NOAC, who is submitted to PCI-S should be kept on the ongoing OAC. But, what if the indication 
for OAC (e.g., because of new-onset AF) arises in a patient who has recently undergone PCI-S and 
therefore is being treated with dual antiplatelet therapy of aspirin and clopidogrel (DAPT)? Should 
warfarin be preferred? Or should a NOAC be used instead? If so, is there a specific NOAC to be 
preferred? Also, is there a preferable dose of the NOAC chosen to be selected? 
 Because of the lack of comparative data between warfarin and NOACs and between the 
individual NOACs, answer the above questions is anything but obvious. To address the everyday 
management of such patients on DAPT also requiring OAC, the available evidence, derived from 3 
different clinical contexts (Fig. 1), will be discussed and practical suggestions proposed. 
 
2. CONSIDERATIONS ON AVAILABLE EVIDENCE 
 Nearly all of the available evidence on the efficacy and safety of TT in AF patients 
undergoing PCI-S has been obtained with warfarin as OAC. Albeit of suboptimal quality (as it 
mostly derives from small size, observational, non-randomized studies or administrative 
databases), and not univocal, such evidence supports TT of warfarin, aspirin and clopidogrel as the 
most effective antithrombotic regimen for the prevention of major adverse cardiac and 
cerebrovascular events (MACCE), including death, myocardial infarction, need for re-
revascularization, stent thrombosis and stroke (8, 9). The reported increase in efficacy however, 
comes at the price of an increased risk of major bleeding (8, 9). Rather consistently, albeit again 
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not univocally, the relative risk (RR) of major bleeding has been shown to be approximately 2.5 
fold that of DAPT (10-18) (Table 2).  
 No such data are currently available for TT of NOAC, aspirin and clopidogrel. The only piece 
of evidence in this regard comes from a post-hoc analysis of the RE-LY trial (4), where the NOAC 
dabigatran at two doses of 110 and 150 mg twice daily was compared to warfarin for the 
prevention of stroke/systemic embolism in patients with AF. In the 812 patients (i.e., 4.5% of the 
entire population) who at some time during the study were simultaneously on the randomized 
OAC treatment and DAPT, the RR of major bleeding compared to OAC alone was 2.31 (97% 
Confidence Intervals [CI] 1.79-2.98), regardless of whether OAC was with warfarin, dabigatran 110 
mg or dabigatran 150 mg (19). When considering that the incidence of major bleeding in AF 
patients treated with either DAPT or warfarin appears comparable, as it has been observed in the 
ACTIVE-W trial (20) (RR 1.10; 95% CI 0.83-1.45; p=0.53), it might be assumed that again the RR of 
major bleeding with TT of the NOAC dabigatran (either 110or 150 mg twice daily) plus aspirin and 
clopidogrel is about 2.5 times that of DAPT alone. 
 In support of the above conjecture are the data coming from the APPRAISE-2 trial (17), 
where in the different clinical context of an acute coronary syndrome (ACS), patients (without AF) 
were randomized to either DAPT or TT of aspirin and clopidogrel plus the NOAC apixaban, which 
was given at the same dose of 5 mg twice daily tested in the ARISTOTLE trial (6) for the prevention 
of stroke/systemic embolism in AF patients. While acknowledging that the study was terminated 
prematurely because of both the absence of benefit on the primary outcome of cardiovascular 
death, myocardial infarction or stroke, and the concomitant significant increase in major bleeding, 
it is of note that again the RR of major bleeding with TT of the NOAC apixaban plus aspirin and 
clopidogrel was about 2.5 times that of DAPT (RR 2.48; 95% CI 1.72-3.58) (Table 3). 
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A higher risk of major bleeding has been reported in the similar ATLAS ACS-2 trial (21) 
where again ACS patients (without AF) were randomized to either DAPT or TT of aspirin and 
clopidogrel plus the NOAC rivaroxaban, which was given at two doses of 2.5 mg (RR 3.46; 95% CI 
2.08-5.77) and 5 mg (RR 4.47; 95% CI 2.71-7.36) twice daily. Because the doses of rivaroxaban 
used in the ATLAS ACS-2 trial (21) correspond to one-quarter and one-half of the dose of 20 mg 
daily tested in the ROCKET AF trial (5) for the prevention of stroke/systemic embolism in AF 
patients, reliable considerations about the true safety of TT of aspirin, clopidogrel and standard AF 
dose of rivaroxaban compared to DAPT cannot be made. Also, because of the so-called “thrombin 
paradox”, according to which thrombin can both promote and inhibit coagulation depending on its 
concentration (as depicted by a U-curve) (22), a further increase in the risk of bleeding with 
standard AF dose of rivaroxaban compared to the low doses tested in the ATLAS ACS-2 trial (21) 
may not necessarily be expected. Whether on the other hand, TT of aspirin, clopidogrel and 
rivaroxaban 2.5 mg twice daily is safe (and effective) in AF patients undergoing PCI-S is currently 
being evaluated in the randomized, multi-center PIONEER AF trial (23). 
Finally supporting the consistency of about a 2.5 increase in RR of clinically significant 
bleeding with TT of NOAC, aspirin and clopidogrel compared to DAPT alone, are the results of a 
meta-analysis where more than 26.000 patients enrolled in randomized, placebo-controlled 
clinical trials comparing DAPT to TT of aspirin and clopidogrel plus a NOAC (either factor Xa 
inhibitor rivaroxaban, apixaban and darexaban or direct thrombin inhibitor dabigatran) after an 
ACS, were evaluated (RR 2.34; 95% CI 2.06-2.66) (18) (Table 2). 
 
3. CHOICE AND MANAGEMENT OF THE ANTICOAGULANT 
 It has been advocated that warfarin should be the preferred agent when the indication for 
OAC arises in patients on DAPT (24, 25). This is because the experience and the evidence regarding 
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TT with warfarin rather than a NOAC as OAC are larger, as are the experience and the evidence 
regarding OAC with warfarin in general. The availability of a specific antidote, namely vitamin K, 
and established non-specific reversal agents, including prothrombin complex concentrates, 
recombinant factor VIIa, and fresh frozen plasma, are additional elements in support of warfarin 
as the preferential OAC. Warfarin however, requires several days before being effective, so that it 
may be questionable whether to start an anticipated short course of warfarin when a NOAC has 
been identified as the best option for long-term treatment. Also, it should not be overlooked that 
the prolonged induction phase of OAC with warfarin is associated with an increased risk of 
bleeding (26). 
 
3.1 Bleeding and reversal agents 
Recent data from clinical trials show that the use of antidotes and reversal agents in 
response to major bleeding during OAC with warfarin is limited, and nonetheless the outcome is 
generally favorable (27, 28). In the same (27, 28), as well as another (29), dataset from the real 
world, a similar favorable outcome of major bleeding has also been shown for all available NOACs, 
in spite of the current lack of a specific antidotes. While these latter are currently in development 
(30), the data mentioned above, as well as the short half-life of NOACs allowing for a nearly 
complete disappearance of the OAC effect within about 48 hours of discontinuation (provided that 
the renal function is normal) (31), apparently make the antidote question a less major issue. 
 
3.2 Warfarin or NOACs 
 Based on all the above, the choice of OAC (i.e., with warfarin or NOAC) to be combined 
with aspirin and clopidogrel in a TT regimen should generally be guided by the same 
considerations made for the choice of OAC in general. Thus, the individual risk of stroke and 
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bleeding (as estimated by the CHA2DS2-VASc and HAS-BLED score, respectively) (32), renal 
function and associated diseases, as well as the anticipated quality of OAC with warfarin (i.e., the 
time the patient is likely to spend with the INR within the therapeutic range, as estimated by the 
SAMe-TT2R2 score) (33, 34), should be taken into account when choosing between warfarin and a 
NOAC (Table 3), largely regardless of the fact that OAC is going to be combined with DAPT. Indeed, 
such strategy is endorsed in the recent ESC Guidelines on Myocardial Revascularization (35). 
 The question then, is whether a specific NOAC should be preferred. Whereas all currently 
available NOACs have been shown to be at least as effective and safe as warfarin in patients with 
AF (4-6) (Table 1), two relevant issues, namely the associated risk of myocardial infarction and 
gastrointestinal bleeding, need to be taken into account. 
 
3.3 Myocardial infarction and gastrointestinal bleeding 
In clinical trials, dabigatran (either 110 or 150 mg twice daily) was shown to be associated 
with an approximate 30% increase in the incidence of myocardial infarction compared to warfarin 
(4, 36, 37) (Table 4). Nonetheless, such effect, which may be attributed to the recognized 
cardioprotective action of warfarin (38), appeared not to have a significant impact on prognosis 
(36). Also, subsequent real-world data disproved the finding of an increased incidence of 
myocardial infarction, which instead was (significantly) reduced (39, 40). At present therefore, the 
fear of a higher risk of myocardial infarction with dabigatran as compared to rivaroxaban and 
apixaban should not be a factor for the selection of a NOAC rather than another in patients on 
DAPT after PCI-S who also need OAC. 
Whereas currently available NOACs taken together increase the risk of gastrointestinal 
bleeding compared to warfarin (41), differences in this regard have been reported in clinical trials 
for the individual NOACs and doses (4-6) (Table 4). In particular, as compared to warfarin the use 
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of dabigatran 110 mg and apixaban show a neutral effect on the incidence of major 
gastrointestinal bleeding, which on the contrary is significantly increased with dabigatran 150 mg 
and rivaroxaban (4-6) (Table 4). Available real-world data confirm that compared to warfarin the 
incidence of gastrointestinal bleeding is decreased with dabigatran 110 mg and increased with 
dabigatran 150 mg (39, 40). Because the gastrointestinal tract is the most frequent site of bleeding 
in patients on TT after PCI-S, the individual NOAC showing (in the absence however, of direct 
comparisons) the greatest safety with regard to this specific aspect should be considered when 
choosing the agent to be added to DAPT. 
 
3.4 Considerations for practice 
In accordance with what discussed above, dabigatran at the reduced dose of 110 mg twice 
daily appears the most valuable OAC option to be added to DAPT, provided that the patient 
displays no features of increased risk of bleeding, and thus is <75 years old, is not underweight 
(i.e., >60 kg), has normal or only mildly impaired renal function (i.e., creatinine clearance >50 
ml/min), and has no history of previous bleeding. In AF patients, dabigatran 110 mg twice daily, 
has been shown as effective as and significantly safer than warfarin regarding the incidence of 
stroke/systemic embolism and major bleeding, respectively (4) (Table 1), comparably safe as 
warfarin regarding the incidence of gastrointestinal bleeding (4) (Table 4), and associated with an 
increased risk of major bleeding when combined to DAPT comparable to that of any combination 
of OAC plus DAPT (19) (Table 2). 
As an alternative, apixaban 5 mg twice daily might be considered. Such regimen has been 
shown in AF patients to be significantly more effective and safer than warfarin regarding the 
incidence of stroke/systemic embolism and major bleeding, respectively (6) (Table 1), and 
comparably safe as warfarin regarding the incidence of gastrointestinal bleeding (6) (Table 4), and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
to be associated, albeit in a population of ACS patients without AF (17), to an increased risk of 
major bleeding comparable to that observed with any combination of OAC plus DAPT (Table 2). 
The options of reduced-dose apixaban 2.5 mg twice daily and rivaroxaban 15 mg once 
daily, which have been tested in AF clinical trials as dose adjustments based on patient 
characteristics (6, 42), seem less suitable. In the absence of factors increasing the risk of bleeding, 
and particularly renal dysfunction, the net clinical benefit (i.e., the combined incidence of MACCE 
and major bleeding) of the above reduced-dose regimens appears uncertain. Whereas in fact, the 
safety might likely be increased, the efficacy on stroke/systemic embolism prevention might be 
insufficient (possibly due to the rapid renal clearance of the drug, as it has been hypothesized for 
the results observed with edoxaban in AF patients with normal renal function enrolled in the 
ENGAGE AF-TIMI 48 trial) (43, 44). Of note however, the anticipated weaker effect on the 
prevention of stroke/systemic embolism exerted by the reduced doses of apixaban and 
rivaroxaban might benefit from the additive effect of DAPT, which reduces the risk of 
stroke/systemic embolism by approximately 30% compared to placebo (45). 
In patients at increased risk of bleeding, including those aged >75 years and/or 
underweight (i.e., < 60 kg) and/or moderate renal impairment (i.e., creatinine clearance 30-50 
ml/min) and/or history of previous bleeding, apixaban at the reduced dose of 2.5 mg twice daily 
appears the most suitable option. Such regimen, which was tested in a subgroup of patients at 
increased risk of bleeding (i.e., presence of ≥ 2 of the following: age ≥ 80 years, body weight ≤ 60 
kg, and serum creatinine ≥ 1.5 mg/dl) who were enrolled in the ARISTOTLE trial (6), showed no 
significant interaction as regards the overall results of a significant superior efficacy and safety of 
apixaban compared to warfarin on stroke/systemic embolism and major bleeding, respectively (6). 
As an alternative, rivaroxaban 15 mg once daily might be considered, essentially when the 
increased risk of bleeding is related to moderate renal impairment (i.e., creatinine clearance 30-50 
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ml/min). In such subgroup of AF patients enrolled in the ROCKET AF trial (5), reduced-dose 
rivaroxaban 15 mg once daily showed no significant interaction as regards the comparable efficacy 
and safety to warfarin on stroke/systemic embolism and major bleeding, respectively (42). 
Whether dabigatran at the reduced dose of 75 mg twice daily, which is currently approved only in 
the U.S.A. for patients with severe renal failure (i.e., creatinine clearance 15-30 ml/min), might be 
an option for patients on DAPT who are at increased risk of bleeding, is at present undetermined. 
Albeit approved in the absence of clinical data, and based only on pharmacokinetic modeling (46), 
initial real-world evidence suggests that such regimen, apparently even when used in the absence 
of severe renal failure, may indeed have a favorable efficacy and safety profile (40). 
Finally, in patients at increased risk of bleeding who are on DAPT after PCI-S and also 
require OAC, standard adjusted-dose warfarin therapy targeted to a reduced INR of 2.0-2.5 may 
be considered. 
A practical algorithm for the selection of OAC in AF patients on DAPT after PCI-S is outlined 
in Fig. 2. 
 
4. CONCLUSIONS 
 While acknowledging that adequate evidence is lacking, and unanswered questions still 
remain when translating clinical trials to practice (47, 48), NOACs might nonetheless be considered 
as the preferred OAC to be added to DAPT in patients recently submitted to PCI-S who develop AF. 
Because of the differences in the individual safety profiles, the NOAC, and dose, associated with 
the lowest bleeding rate, especially at the gastrointestinal tract (which is the site most frequently 
affected in patients on TT), should be carefully selected. Further adjustment in the choice of NOAC 
and dose should be considered in the patient at increased risk of bleeding. Whether the dual 
combination of NOAC and one antiplatelet agent, namely the newer and more potent P2Y12-
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receptor inhibitors ticagrelor and prasugrel, may have a more favorable net clinical benefit 
compared to TT, is as yet undetermined and therefore not recommended. Ongoing clinical trials 
are addressing this issue (23, 49).  
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LEGEND OF FIGURE 
Figure 1. Clinical contexts from which evidence regarding triple therapy of OAC, aspirin and 
clopidogrel is derived. 
OAC = oral anticoagulation; AF = atrial fibrillation, ACS = acute coronary syndrome; PCI-S = 
percutaneous coronary intervention with stent  
Figure 2. Suggested algorithm for the selection of OAC, and dose, to be combined with DAPT in 
patientsrecently submitted to PCI-S who develop AF. 
DAPT = dual antiplatelet therapy of aspirin and clopidogrel; AF = atrial fibrillation; PCI-S = 
percutaneous coronary intervention with stent; CrCl = creatinine clearance; INR = International 
Normalized Ratio; BID = twice daily 
a if ongoing, P2Y12-receptor inhibitor prasugrel or ticagrelor should be interrupted and switching to 
clopidogrel performed 
bas an alternative, rivaroxaban 15 mg once daily may be considered (essentially in the presence of 
moderate renal impairment, i.e., creatinine clearance 30-50 ml/min) 
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Table 1. Relative risk (95% Confidence Interval) of major clinical outcomes with NOACs vs. warfarin in AF 
randomized clinical trials. 
Study  NOAC Stroke/Systemic embolism Major Bleeding ICH 
RE-LY (4) Dabigatran 110 mg BID 0.91 (0.74-1.11)a 0.80 (0.69-0.93)d 0.31 (0.20-0.47)e 
Dabigatran 150 mg BID 0.66 (0.53-0.82)a b 0.93 (0.81-1.07) 0.40 (0.27-0.60)e 
ROCKET AF (5) Rivaroxaban 20 mg OD 0.88 (0.74-1.03)a 1.04 (0.90-1.20) 0.67 (0.47-0.93)f 
ARISTOTLE (6) Apixaban 5 mg BID 0.79 (0.66-0.95)c 0.69 (0.60-0.80)e 0.42 (0.30-0.58)e 
ap<0.001 for non-inferiority; bp<0.001 for superiority;cp=0.01; dp = 0.03; ep<0.001; fp=0.02 
 
AF = atrial fibrillation; BID = twice daily; ICH = intracranial hemorrhage; NOAC = non vitamin K-antagonist oral 
anticoagulant; OD = once daily 
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Table 2. Relative risk of major bleeding with TT of oral anticoagulant (either VKA or NOAC), aspirin and clopidogrel 
vs. DAPT of aspirin and clopidogrel in various studies. 
Author/Study Type of study OAC N. of patients Population RRa 95% CI 
Zhao HJ et al. (8) Meta-analysis VKA 1996 OAC 2.12 1.05-4.29 
Singh PP et al. (9) Meta-analysis VKA 1482 OAC 2.74 1.08-6.98 
Andrade JG et al. (10) Meta-analysis VKA 2499 b OAC 2.87 1.47-5.62 
Average      2.57  
Brulotte S et al. (11) Cohort, retrospective  VKA 183 OAC 1.44 0.13-15.53 
Olson KL et al. (12) Cohort, retrospective  VKA 175 OAC 4.84 2.38-9.85 
MUSICA (13) Registry, prospective  VKA 405 OAC 3.49 0.46-26.48 
HORIZONS-AMI (14) RCT c VKA 3320 OAC 2.63 1.69-4.09 
Rubboli A et al. (15) Cohort, retrospective  VKA 632 OAC 2.50 0.49-12.58 
WAR-STENT (16) Registry, prospective    VKA 401 OAC 1.73 0.23-12.85 
Average     2.77  
APPRAISE-2 (17) RCT NOAC d 7392 ACS 2.48 1.72-3.58 
Oldgren J et al. (18) Meta-analysis NOAC e 26731 ACS 2.34 f 2.06-2.66 
Average      2.41  
Overall average     2.65  
a as reported in the original study or calculated as: a/(a+b) divided by c/(c+d), where a and b are the number of 
patients with and without major bleeding, respectively in the TT group, and c and d the number of patients with 
and without major bleeding, respectively in the DAPT group 
b on TT only 
c post-hoc analysis 
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d apixaban 
e apixaban, darexaban, rivaroxaban and dabigatran 
f major and non-major clinically relevant bleeding 
 
CI = Confidence Interval;  DAPT = dual antiplatelet therapy; NOAC = non vitamin K-antagonist oral anticoagulant; 
RCT = randomized clinical trial; RR = relative risk; TT = triple therapy; VKA = vitamin K-antagonist 
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Table 3.  Suggestions regarding the choice of OAC in AF patients based on currently recommended scores for risk stratification 
(1, 32-34). 
Score   Points  Interpretation Suggestions 
CHA2DS2-VASc 0 Low risk of stroke No antithrombotic therapy 
≥ 1 Moderate-high risk of stroke OAC (with either warfarin or NOACs) 
HAS-BLED 0-2 Low-moderate risk of bleeding Consider either warfarin or NOACs 
≥ 3 High risk of bleeding  Preferably consider NOACs (associated with less 
bleeding than warfarin) 
SAMe-TT2R2 0-1 High TTR (> 65-70%) on warfarin likely Consider either warfarin or NOACs 
≥ 2 High TTR (> 65-70%) on warfarin unlikely Preferably consider NOACs 
 
CHA2DS2-VASc: Congestive heart failure 1 point, Hypertension 1 point, Age (≥ 75 years) 2 points, Diabetes 1 point, 
previous Stroke 2 points, Vascular disease (previous myocardial infarction, peripheral artery disease, aortic plaque) 
1 point, Age 65-74 years 1 point, Sex category (female) 1 point 
HAS-BLED: Hypertension (systolic blood pressure > 160 mmHg) 1 point, Abnormal renal (chronic dialysis or renal 
transplantation or serum creatinine ≥ 200 μmol/L) and liver disease (chronic hepatic disease or biochemical 
evidence of significant hepatic derangement) 1 point each, previous Stroke 1 point, Bleeding (history of and/or 
predisposition to) 1 point, Labile INRs (TTR < 60%) 1 point, Elderly (age > 65 years) 1 point, Drugs (concomitant 
antiplatelets, non-steroidal anti-inflammatory drugs) or alcohol 1 point each 
SAMe-TT2R2: Sex (female) 1 point, Age (< 60 years) 1 point, Medical history (≥ 2 of: hypertension, diabetes, coronary 
artery disease/myocardial infarction, peripheral artery disease, congestive heart failure, previous stroke, pulmonary 
disease, and hepatic or renal disease) 1 point, Treatment (interacting drugs, such as amiodarone for rhythm control) 
1 point, Tobacco (within 2 years) 2 points, Race (nonwhite) 2 points  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
 
 
  
AF = atrial fibrillation; NOAC = non vitamin-K oral anticoagulants;  OAC = oral anticoagulation; TTR = Time in 
Therapeutic Range 
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Table 4. Relative risk (95% Confidence Intervals) of myocardial infarction and gastrointestinal 
bleeding with NOACs vs. warfarin in AF randomized clinical trials. 
Study  NOAC Myocardial Infarction Gastrointestinal Bleeding 
RE-LY (4) Dabigatran 110 mg BID 1.35 (0.98-1.87) 1.10 (0.86-1.41) 
Dabigatran 150 mg BID 1.38 (1.00-1.91) a 1.50 (1.19-1.89) b 
ROCKET AF (5) Rivaroxaban 20 mg OD 0.81 (0.63-1.06) 1.60 (1.29-1.98) b 
ARISTOTLE (6) Apixaban 5 mg BID 0.88 (0.66-1.17) 0.89 (0.70-1.15) 
ap=0.048; b p<0.001 
AF = atrial fibrillation; BID = twice daily; NOACs = non vitamin K-antagonist oral anticoagulant; OD 
= once daily 
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HIGHLIGHTS 
 There is consensus on the antithrombotic therapy for AF patients undergoing PCI 
 There is uncertainty on the antithrombotic therapy for PCI patients developing AF 
 The risk of bleeding with triple therapy is comparable regardless of type of OAC 
 NOACs might be selected as the preferred OAC to be combined in triple therapy 
 The dose of selected NOAC should be individualized based on patient characteristics 
